WAVE Life Sciences (WVE) saw its stock price plummet by 5.22% in Monday's trading session following the release of its third-quarter financial results, which fell short of analyst expectations. The biotechnology company, focused on developing precision medicines for patients with debilitating diseases, reported disappointing figures across key financial metrics.

The company posted a quarterly loss of $0.32 per share, wider than the FactSet analyst consensus estimate of a $0.30 loss. While this represents an improvement from the $0.47 loss per share reported in the same quarter last year, it still missed the mark set by Wall Street. Revenue for the quarter came in at $7.608 million, significantly below the analyst expectations of $11.13 million, despite showing a substantial increase from the negative revenue reported in the previous year.

Despite the negative market reaction, WAVE Life Sciences highlighted its strong cash position, reporting $196.2 million in cash and cash equivalents as of September 30, 2025. The company stated that this, combined with additional funds received after the quarter's end, is expected to fund operations through the second quarter of 2027. WAVE Life Sciences also provided updates on its clinical programs, including progress with WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, as well as preparations for a potentially registrational Phase 2/3 study of WVE-003 in Huntington's disease. However, these positive aspects were overshadowed by the financial underperformance, leading to the sharp decline in stock price.